These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 10762744)

  • 1. Estimates of the lifetime costs of breast cancer treatment in Canada.
    Will BP; Berthelot JM; Le Petit C; Tomiak EM; Verma S; Evans WK
    Eur J Cancer; 2000 Apr; 36(6):724-35. PubMed ID: 10762744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs.
    Will BP; Le Petit C; Berthelot JM; Tomiak EM; Verma S; Evans WK
    Br J Cancer; 1999 Mar; 79(9-10):1428-36. PubMed ID: 10188886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Br J Cancer; 1995 Nov; 72(5):1270-7. PubMed ID: 7577481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lifetime costs of colon and rectal cancer management in Canada.
    Maroun J; Ng E; Berthelot JM; Le Petit C; Dahrouge S; Flanagan WM; Walker H; Evans WK
    Chronic Dis Can; 2003; 24(4):91-101. PubMed ID: 14733758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer: better care for less cost. Is it possible?
    Evans WK; Will BP; Berthelot JM; Logan DM; Mirsky DJ; Kelly N
    Int J Technol Assess Health Care; 2000; 16(4):1168-78. PubMed ID: 11155836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
    Millar JA; Millward MJ
    Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimates of the lifetime direct costs of treatment for metastatic breast cancer.
    Berkowitz N; Gupta S; Silberman G
    Value Health; 2000; 3(1):23-30. PubMed ID: 16464178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canada's Population Health Model (POHEM): a tool for performing economic evaluations of cancer control interventions.
    Will BP; Berthelot JM; Nobrega KM; Flanagan W; Evans WK
    Eur J Cancer; 2001 Sep; 37(14):1797-804. PubMed ID: 11549434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
    Rocchi A; Verma S
    Support Care Cancer; 2006 Sep; 14(9):917-27. PubMed ID: 16596419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran.
    Ansaripour A; Zendehdel K; Tadayon N; Sadeghi F; Uyl-de Groot CA; Redekop WK
    PLoS One; 2018; 13(10):e0205079. PubMed ID: 30273393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The economics of lung cancer management in Canada.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Lung Cancer; 1996 Feb; 14(1):19-29. PubMed ID: 8696718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic breast cancer: we do need primary cost data.
    Bonastre J; Jan P; Barthe Y; Koscielny S
    Breast; 2012 Jun; 21(3):384-8. PubMed ID: 22520336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data.
    Lamerato L; Havstad S; Gandhi S; Jones D; Nathanson D
    Cancer; 2006 May; 106(9):1875-82. PubMed ID: 16572409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
    Beauchemin C; Letarte N; Mathurin K; Yelle L; Lachaine J
    J Med Econ; 2016 Jun; 19(6):619-29. PubMed ID: 26850287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.
    Grover SA; Coupal L; Zowall H; Rajan R; Trachtenberg J; Elhilali M; Chetner M; Goldenberg L
    CMAJ; 2000 Apr; 162(7):987-92. PubMed ID: 10763396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advanced breast cancer: an evaluation of the cost of recurrence].
    Bercez C; Lebrun T; Bonneterre ME; Selke B; Lenne X; Bonneterre J
    Bull Cancer; 1999 Jun; 86(6):585-90. PubMed ID: 10417432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment pathways, resource use and costs in the management of small cell lung cancer.
    Oliver E; Killen J; Kiebert G; Hutton J; Hall R; Higgins B; Bourke S; Paschen B
    Thorax; 2001 Oct; 56(10):785-90. PubMed ID: 11562518
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.